221 Crescent Street
Building 17 Suite 102b
Waltham, MA 02453
United States
650-394-5230
https://www.apogeetherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 91
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Michael Thomas Henderson M.D. | CEO & Director | 1.17M | N/D | 1990 |
Ms. Jane Pritchett V. Henderson | Chief Financial Officer | 843.64k | N/D | 1966 |
Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer | 870.83k | N/D | 1986 |
Ms. Noel Kurdi | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Matthew Batters J.D. | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1976 |
Ms. Emily Cox | VP & Head of People | N/D | N/D | N/D |
Dr. Rebecca Dabora Ph.D. | Chief Development Officer | N/D | N/D | 1960 |
Ms. Wendy Aspden-Curran | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
Dr. Drew Badger Ph.D. | Senior VP and Head of Regulatory Affairs & Toxicology | N/D | N/D | N/D |
Ms. Monica Forbes | Senior Vice President of Finance | N/D | N/D | 1976 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
La calificación ISS Governance QuickScore de Apogee Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.